Distribution of pretreatment risk factors by randomized postremission regimen
. | HiDAC alone, no. (%) . | Multiagent CT, no. (%) . | Total, no. (%) . |
|---|---|---|---|
| Age, y | |||
| Younger than 30 | 36 (24) | 30 (19) | 66 (21) |
| 30-39 | 34 (22) | 36 (23) | 70 (23) |
| 40-49 | 44 (29) | 52 (33) | 96 (31) |
| 50-59 | 39 (25) | 38 (24) | 77 (25) |
| WBC count, × 103/μL | |||
| 7 or lower | 52 (35) | 44 (29) | 96 (32) |
| 7.1-30 | 42 (28) | 50 (32) | 92 (30) |
| Greater than 30 | 56 (37) | 60 (38) | 116 (38) |
| CD56 | |||
| Negative | 84 (90) | 86 (84) | 170 (87) |
| Positive | 9 (10) | 16 (16) | 25 (13) |
| Cytogenetic risk groups (cumulative incidence of relapse)* | |||
| Favorable | 27 (18) | 21 (13) | 48 (16) |
| Intermediate | 54 (35) | 66 (42) | 120 (39) |
| Unfavorable | 11 (7) | 4 (3) | 15 (5) |
| Not classified† | 5 (3) | 5 (3) | 10 (3) |
| t(15;17) | 5 (3) | 4 (3) | 9 (3) |
| Inadequate | 51 (33) | 56 (36) | 107 (35) |
| FAB | |||
| Non-M4 or M5 | 108 (71) | 102 (65) | 210 (68) |
| M4 or M5 | 45 (29) | 54 (35) | 99 (32) |
. | HiDAC alone, no. (%) . | Multiagent CT, no. (%) . | Total, no. (%) . |
|---|---|---|---|
| Age, y | |||
| Younger than 30 | 36 (24) | 30 (19) | 66 (21) |
| 30-39 | 34 (22) | 36 (23) | 70 (23) |
| 40-49 | 44 (29) | 52 (33) | 96 (31) |
| 50-59 | 39 (25) | 38 (24) | 77 (25) |
| WBC count, × 103/μL | |||
| 7 or lower | 52 (35) | 44 (29) | 96 (32) |
| 7.1-30 | 42 (28) | 50 (32) | 92 (30) |
| Greater than 30 | 56 (37) | 60 (38) | 116 (38) |
| CD56 | |||
| Negative | 84 (90) | 86 (84) | 170 (87) |
| Positive | 9 (10) | 16 (16) | 25 (13) |
| Cytogenetic risk groups (cumulative incidence of relapse)* | |||
| Favorable | 27 (18) | 21 (13) | 48 (16) |
| Intermediate | 54 (35) | 66 (42) | 120 (39) |
| Unfavorable | 11 (7) | 4 (3) | 15 (5) |
| Not classified† | 5 (3) | 5 (3) | 10 (3) |
| t(15;17) | 5 (3) | 4 (3) | 9 (3) |
| Inadequate | 51 (33) | 56 (36) | 107 (35) |
| FAB | |||
| Non-M4 or M5 | 108 (71) | 102 (65) | 210 (68) |
| M4 or M5 | 45 (29) | 54 (35) | 99 (32) |